U.S. Markets open in 1 hr 13 mins

  • Gold

    1,802.60
    +6.30 (+0.35%)
     

  • EUR/USD

    1.1606
    -0.0039 (-0.3366%)
     

  • 10-Yr Bond

    1.6550
    0.0000 (0.00%)
     

  • Vix

    15.83
    +0.82 (+5.46%)
     

  • GBP/USD

    1.3752
    -0.0007 (-0.0523%)
     

  • USD/JPY

    113.6700
    +0.2100 (+0.1851%)
     

  • BTC-USD

    62,953.56
    +2,767.58 (+4.60%)
     

  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     

  • FTSE 100

    7,233.78
    +29.23 (+0.41%)
     

  • Nikkei 225

    28,600.41
    -204.44 (-0.71%)
     
WATCH:

Yahoo Finance's 2021 All Markets Summit — The Path Forward

October 25 from 9:00 a.m to 5 p.m. ET

Infinity Pharma Shows Encouraging Eganelisib/Nivolumab Combo Data In Urothelial Cancer Study

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

  • Infinity Pharmaceuticals Inc (NASDAQ: INFI) has announced a data presentation from MARIO-275 Phase 2 study evaluating eganelisib combined with Bristol-Myers Squibb's Opdivo (nivolumab) in platinum-refractory, I/O naïve patients with advanced urothelial cancer at the 2021 ASCO Genitourinary Cancers Symposium.

  • In the overall population, the combination of eganelisib with nivolumab demonstrated an increase over nivolumab monotherapy in overall response rate (30% vs. 25%); disease control rate (55% vs. 31%); best responses of complete response (12% vs. 6%); stable disease (24% vs. 6%).

  • Data also showed that the addition of eganelisib on top of 2L standard of care nivolumab was well-tolerated and led to clear benefits for PD-L1 low patients, with an over 85% increase in ORR vs. the control arm. 

  • PD-L1 negative patients demonstrated an extended progression-free survival, reflecting a 46% reduction in the probability of progression of 9.1 weeks on the combination arm versus 7.9 weeks on the control arm.

  • Increased immune activation and decreased immune suppression were observed in combination therapy compared to monotherapy across PD-L1 negative and positive patients.

  • Registration-enabling study in PD-L1 low metastatic urothelial cancer is planned next.

  • Price Action: INFI stock increased 20% at $4.74 in premarket trading on the last check Thursday. 

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Recommended Stories

  • Analysis-From zero to $12 billion; investors chase Trump stock hype

    Donald Trump has united some of his supporters and detractors in buying shares in his new company and hoping to score a big win. Anthony Nguyen, a 49-year-old software consultant from Austin, Texas, is a Republican who refused to vote for the former U.S. president in last year's election. Last week he joined the millions of online day traders who drove up the value of the company that will house Trump's new social media venture to almost $12 billion.

  • 2 Biotech Stocks That Could Go Parabolic This Week

    The most recent examples are the explosive upward moves by shares of Donald Trump's social media-associated stocks, Digital World Acquisition (NASDAQ: DWAC) and Phunware (NASDAQ: PHUN). Last week, Digital World Acquisition's shares rose by as much as 1,500%. Mergers and acquisitions have been the name of the game for biotech investors this year.

  • Elon Musk reveals his crypto buys

    Tesla's CEO and crypto proponent Elon Musk said he has no investment in Shiba Inu.

  • Got $5,000? 2 Tech Stocks to Buy and Hold for the Long Term

    Many people don't realize that although the benchmark is comprised of the 500 largest stocks on the market, over 27% of those companies are tech stocks, the largest component of the index. If generating serious wealth is one of your financial goals, it's perfectly achievable by practicing a buy-and-hold strategy. A great place to start would be with the following high-growth tech stocks.

  • Are Atea Pharmaceuticals, Agenus, Novavax, and Ocular Therapeutix Bad News Buy?

    Biotech stocks are in a slump. Despite numerous wins in the high-profile areas of COVID-19 and cancer therapy, the industry has failed to excite investors this year -- as seen in the 12% year-to-date fall in the the bellwether SPDR S&P Biotech ETF. Risk-tolerant growth investors appear to be favoring other vehicles over biotech in 2021, such as the red-hot cryptocurrency Shiba Inu (CRYPTO: SHIB), electric-vehicle giant Tesla (NASDAQ: TSLA), and emerging social media plays such as Digital World Acquisition (NASDAQ: DWAC) and Phunware (NASDAQ: PHUN).

  • Will Ford's Q3 Earnings Crush Wall Street's Estimates Again?

    Ford Motor Company (NYSE: F) will report its third-quarter results after the U.S. markets close on Wednesday, Oct. 27. Wall Street analysts polled by Thomson Reuters expect Ford to report adjusted earnings per share of $0.26 on automotive revenue of $33.04 billion. Sales of Ford's F-Series pickups fell 22% in the third quarter, despite high demand, as chip supplies limited production.

  • How Low Can Moderna Stock Go?

    Moderna (NASDAQ: MRNA) is no longer the seemingly invincible, high-flying stock that it once was. There are plenty of reasons why the vaccine stock has lost some of its mojo. To me, there's a much more important question to attempt to answer: How low can Moderna stock actually go?

  • Blackstone Inc. (NYSE:BX) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

    It looks like Blackstone Inc. ( NYSE:BX ) is about to go ex-dividend in the next 3 days. The ex-dividend date is one...

  • Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH): When Will It Breakeven?

    Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) is possibly approaching a major achievement in its business, so we would...

  • Cathie Wood Tells Jack Dorsey Deflationary Forces Will Eclipse Supply-Chain Havoc

    (Bloomberg) -- Deflationary forces will overcome the supply-chain induced price pressures buffeting the world economy, Ark Investment Management LLC founder Cathie Wood said in a tweet after a Jack Dorsey post on hyperinflation.Most Read from BloombergCities' Answer to Sprawl? Go Wild.Hamburg Is at the Heart of Germany’s Growing Dilemma Over ChinaWhy Americans and Britons Are Rushing to Buy Idyllic Homes in ItalyOne of California’s Wealthiest Counties Could Run Out of Water Next SummerThe Top Mo

  • 3 Dividend Stocks Under $10 With at Least 8% Dividend Yield

    Every investor wants to see his stocks pay off – or he wouldn’t be in the markets. But finding the right investment, the ‘one’ that will bring profits, no matter what direction the overall markets take, can sometimes be challenging. The two simplest courses of action an investor can take to ensure solid returns are based on common sense. The first is, to buy low and sell high. That is, find a cheap stock with sound fundamentals and good prospects for growth – and buy in to take advantage of the

  • Tesla Shares Set to Touch New Record as Good News Pile Up

    (Bloomberg) -- Tesla Inc. shares are poised to reach a new all-time high on Monday for the third straight trading session.Most Read from BloombergCities' Answer to Sprawl? Go Wild.Hamburg Is at the Heart of Germany’s Growing Dilemma Over ChinaWhy Americans and Britons Are Rushing to Buy Idyllic Homes in ItalyOne of California’s Wealthiest Counties Could Run Out of Water Next SummerThe Top Money Maker at Deutsche Bank Reaps Billions From SingaporeIt’s already looking to be a good day for the elec

  • The 1929 Stock Market Crash Caught Nearly Everyone Off Guard. Are We Headed for a Similar Fate?

    The Great Crash that began on Oct. 24, 1929, demolished every investing strategy that didn’t include stuffing cash into mattresses. Are we on a similar trajectory now?

  • PayPal Rules Out Pinterest Acquisition 'At This Time'

    PayPal rose while PINS stock tumbled after the payments giant said it's pursuing a Pinterest acquisition "at this time."

  • 3 No-Brainer Stocks to Invest $50 in Right Now

    The first no-brainer stock patient investors can buy right now with $50 is mobile gaming platform company Skillz (NYSE: SKLZ). Shares of Skillz have lost more than three-quarters of their value since peaking in early February. What makes Skillz such an intriguing company is that it's avoided the costly development side of the equation and focused its efforts on being a platform where gamers can compete against each other for cash prizes.

  • XPeng Hosted A Technology Day. It Revealed Three Things and a Flying Car.

    XPeng hosted a technology event over the weekend and showcased its latest charging, self driving and robotics technology. There was a flying car, too.

  • 3 Inflation-Proof Dividend Stocks Begging to Be Bought

    For the stock market, inflationary pressures have historically tended to be something of a mixed bag: Many companies struggle, while others put up a relatively strong performance and can even benefit from unusual economic and monetary dynamics. In order to put investors on the trail of stocks that could perform well in this age of elevated inflation, we put together a panel of Motley Fool contributors and tasked them with identifying top picks for riding out these uncertain times. Keith Noonan (Broadcom): Semiconductors make the world go round.

  • Kimberly-Clark announces profit warning as company prepares to raise prices

    Kimberly-Clark Corp. shares fell 2.7% in Monday premarket trading after the consumer goods company reported third-quarter earnings that missed expectations and lowered its earnings guidance. Net income totaled $469 million, or $1.39 per share, compared with $472 million, or $1.38 per share, last year. Adjusted EPS of $1.62 missed the FactSet consensus for $1.65. Sales of $5.01 billion were up from $4.68 billion last year and ahead of the FactSet consensus for $4.99 billion. "Our earnings were ne

  • 3 Tech Stocks You Should Own This Earnings Season

    Earnings season is upon us and companies are now reporting on their late summer financial results in earnest. Stock prices can go wild during these periods as companies post figures that either beat or fall short of investor expectations. Three tech names that recently reported are IBM (NYSE: IBM), Duck Creek Technologies (NASDAQ: DCT), and Lam Research (NASDAQ: LRCX).

  • 11 Best High Dividend Stocks To Buy According To Billionaire Cooperman

    In this article, we discuss the 11 best high dividend stocks to buy according to billionaire Cooperman. If you want to skip our detailed analysis of Cooperman’s history, investment philosophy, and hedge fund performance, go directly to the 5 Best High Dividend Stocks To Buy According To Billionaire Cooperman. Leon Cooperman is an American hedge […]